Study on the Effectiveness and Safety of VRT in Patients With Visual Field Defects
1 other identifier
interventional
58
0 countries
N/A
Brief Summary
The goal of this clinical trial is to learn if visual restoration therapy (VRT) (a type of treatment that aims to improve vision) works to the visual rehabilitation of patients with visual field defects. It will also learn about the safety of VRT. The main questions it aims to answer are:
- Can visual reconstruction therapy help expand the visual field in patients with visual field defects?
- What medical problems do patients with visual field defects experience during the procedure of VRT? Researchers will look at how patients with visual field defects who use a visual aid in combination with VRT and those who use a visual aid only, compare the visual field expansion at three months to see how well visual reconstruction therapy works. Participants will:
- will undergo a specialized visual function assessment and be provided with a pair of appropriate vision aids.
- Visit the clinic at one month and three months after enrolment for review of visual function and completion of a Chinese-version Low Vision Quality of Life (CLVQOL) questionnaire.
- Participants receiving VRT will additionally undergo 30 minutes of VRT three times per week for 3 months.
- Keep a diary for their symptoms and severity and frequency of occurrence during treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Apr 2025
Typical duration for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 30, 2025
CompletedFirst Posted
Study publicly available on registry
April 6, 2025
CompletedStudy Start
First participant enrolled
April 15, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 30, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 30, 2027
April 6, 2025
March 1, 2025
2.7 years
March 30, 2025
April 4, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
visual field mean deviation (MD) value
using the Humphrey Field Analyzer 30-2 test to obtain MD values
A total of 3 examinations were performed during the trial: before treatment, after 1 month of treatment, and after 3 months of treatment.
Study Arms (2)
VRT treatment group
EXPERIMENTALThe participants will be provided with a pair of appropriate vision aids and will undergo 3 times 30-minute visual restoration therapy (VRT) training per week for three months.
control group
NO INTERVENTIONParticipants will be provided with a pair of appropriate vision aids, however without any visual treatment.
Interventions
In this study, we used a reversing checkerboard pattern as a stimulus and acted on the relatively dark spots area of the patient's visual field.
Eligibility Criteria
You may qualify if:
- Participants with a clear diagnosis of visual field defects.
- Participants were between 18 and 80 years of age (including borderline values);
- Participants have been treated for their primary disease and conditions are stable;
- Participants are not at significant risk of vision loss in the last three months;
- Participants do not have planned intraocular surgery during the trial period;
- Participants can understand the trial protocol and sign informed consent.
You may not qualify if:
- Participants diagnosed as blindness;
- Participants with a previous history of seizures or other psychiatric disorders;
- Participants with cognitive impairments;
- Participant's attention span is less than 30 minutes;
- Participants had conditions such as significant ptosis or severe dry eye;
- Participants who were in poor general health or who could not cooperate in completing the study protocol for some reasons such as transport.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Officials
- PRINCIPAL INVESTIGATOR
Zhen Li, MD. and PHD.
Ophthalmology Department, Xuanwu Hospital,Capital Medical University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 30, 2025
First Posted
April 6, 2025
Study Start
April 15, 2025
Primary Completion (Estimated)
December 30, 2027
Study Completion (Estimated)
December 30, 2027
Last Updated
April 6, 2025
Record last verified: 2025-03
Data Sharing
- IPD Sharing
- Will not share